Skip to content

Endo reports final results, affirms 2017 guidance

May 9, 2017
  • First-quarter 2017 revenues increased 8 percent from prior year to $1,038 million
  • First-quarter 2017 U.S. Generic Pharmaceuticals revenue increased 24 percent to $722 million
  • First-quarter 2017 reported $0.74 diluted (GAAP) loss per share from continuing operations
  • First-quarter 2017 adjusted diluted earnings per share (EPS) from continuing operations increased 14 percent to $1.23
  • First-quarter 2017 reported (GAAP) consolidated net loss of $174 million
  • First-quarter 2017 adjusted EBITDA increased 21 percent to $478 million
  • Company reaffirms 2017 full-year revenues, adjusted EBITDA and adjusted diluted EPS financial guidance

http://prn.to/2qYyQwg

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: